Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online for The Annals of Pharmacotherapy.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More